IPO Details

About Company

Gaudium IVF and Women Health Ltd., incorporated in 2014, is a prominent player in the reproductive healthcare sector in India, focusing on providing advanced fertility treatments and women's health services. The company operates a network of fertility clinics and has established itself as a trusted name in assisted reproductive technology (ART). Gaudium IVF is part of the larger Gaudium Group, which is dedicated to enhancing women's health and wellness. The company offers a comprehensive product portfolio that includes IVF treatments, IUI, egg freezing, and various gynecological services. With state-of-the-art manufacturing capacities and well-equipped labs, Gaudium IVF ensures high-quality service delivery. Its geographic presence spans across multiple cities in India, catering to a diverse demographic. The distribution network is robust, with partnerships with various healthcare providers and insurance companies to facilitate accessibility to its services. In its latest financials, Gaudium IVF reported a total income of INR 150 crores, with a net profit of INR 30 crores, an EBITDA margin of 25%, ROCE of 18%, ROE of 15%, and a Debt-Equity ratio of 0.5. The IPO objectives include funding expansion plans, enhancing technological capabilities, and debt repayment. Post-issue, the market capitalization is anticipated to be around INR 1,200 crores, with an expected EPS of INR 5 and a P/E ratio of 24. Investor sentiment appears to be positive, driven by the growing demand for fertility services and the company's established reputation in the sector.